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Abstract
Liver cancer comprises a group of malignant tumors, among which hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC) are the most common. ICC is especially pernicious and associated with poor clinical outcome.
Studies have shown that a subset of human ICCs may originate from mature hepatocytes. However, the mechanisms driving
the trans-differentiation of hepatocytes into malignant cholangiocytes remain poorly defined. We adopted lineage tracing
techniques and an established murine hepatocyte-derived ICC model by hydrodynamic injection of activated forms of AKT
(myr-AKT) and Yap (YapS127A) proto-oncogenes. Wild-type, Notch1flox/flox, and Notch2flox/flox mice were used to
investigate the role of canonical Notch signaling and Notch receptors in AKT/Yap-driven ICC formation. Human ICC and
HCC cell lines were transfected with siRNA against Notch2 to determine whether Notch2 regulates biliary marker
expression in liver tumor cells. We found that AKT/Yap-induced ICC formation is hepatocyte derived and this process is
strictly dependent on the canonical Notch signaling pathway in vivo. Deletion of Notch2 in AKT/Yap-induced tumors
switched the phenotype from ICC to hepatocellular adenoma-like lesions, while inactivation of Notch1 in hepatocytes did
not result in significant histomorphological changes. Finally, in vitro studies revealed that Notch2 silencing in ICC and HCC
cell lines down-regulates the expression of Sox9 and EpCAM biliary markers. Notch2 is the major determinant of
hepatocyte-derived ICC formation in mice.
Introduction
Primary liver cancer is the second most common cause of
cancer mortality in the world, with increasing incidence
globally [1, 2]. Hepatocellular carcinoma (HCC) and
intrahepatic cholangiocarcinoma (ICC) are the two most
prevalent liver tumor types. Most ICCs are diagnosed at
advanced stage and only a few patients are suitable for
surgery at the time of diagnosis. For patients with
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inoperable ICC, very limited treatment options exist.
According to the American Cancer Society (www.cancer.
org), the 5-year survival rate for ICC patients with localized
disease is ~15%, and only 2% for patients with distal
metastasis. ICC has been traditionally considered to be
derived from biliary epithelial cells (BEC). However, recent
studies have indicated that adult hepatocytes can transdif-
ferentiate into BEC-like cell in various chronic liver dis-
eases, which then may further develop into malignant cells
[3, 4]. In accordance with this hypothesis, recent epide-
miology studies have shown that in Western countries,
where biliary tract infection rate is extraordinarily low,
chronic infections by hepatitis B or C virus as well as
alcohol abuse are major risk factors for ICC [5], as
described for HCC. Studies from our and other laboratories
also confirmed that ICC can originate from mature hepa-
tocytes in mice following activation of the Notch signaling
[6, 7].
Notch is a highly conserved pathway during develop-
ment. This pathway is critical for biliary cell coordination
and tubule formation [8]. The structure, homeostasis, and
carcinogenesis of the liver relies on the Notch cascade [9,
10]. In mammals, canonical Notch pathway consists of four
receptors (Notch1, Notch2, Notch3, and Notch4) and
mainly two types of ligands, Serrate/Jagged (Jagged1 and
Jagged2) and Delta-like (DLL1, DLL3, and DLL4) [11–13].
This cascade is activated by direct cell–cell interaction, with
subsequent cleavage of the Notch receptor extracellular
domain (NECD). This structural change leads to the release
of the Notch intracellular domain (NICD), which translo-
cates into the nucleus and recruits coactivators, such as
Mastermind-like proteins (MAML1, MAML2, or
MAML3). Together with the recombinant signal-binding
protein for immunoglobulin kappa J region (RBPJ) tran-
scription factor, they form the transcription complex
responsible for the induction of Notch target genes [9, 14].
The most studied Notch signaling targets are hairy/enhancer
of split (Hes) and hairy/enhancer of split related with
YRPW motif (Hey) families. Another emerging target is
Fig. 1 AKT/Yap-induced intrahepatic cholangiocarcinomas (ICC)
derived from hepatocytes. a Study design. AAV-Tbg-Cre was injected
intravenously to generate EYFP expression. AKT and Yap were co-
injected hydrodynamically to induce tumor development. b The upper
panels show immunofluorescence of CK19 and EYFP. The lower
panels are representative staining of HA tag and EYFP. Note that
EYFP was only expressed in hepatocytes, while surrounding
mesenchymal cells did not show red fluorescence. Tumor is labeled as
T and non-tumor is labeled as NT. Magnification: 100×
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Notch-regulated ankyrin repeat protein (Nrarp), which is
activated by the RBPJ-dependent Notch pathway [15].
Both Notch1 and Notch2 receptors are expressed in the
liver, but whether they play distinct or redundant roles along
hepatocarcinogenesis remains an unanswered issue. Notch1
is considered a tumor suppressor in HCC [16, 17], but a
bona fide oncogene in ICC [18]. Deprivation of Notch1
results in continuous proliferation of hepatocytes [19].
Notch2, on the other hand, seems to be crucial for the dif-
ferentiation of BECs and is required for normal perinatal
and postnatal intrahepatic bile duct (IHBD) development
[20, 21]. The canonical Notch2 signaling can determine
Fig. 2 Notch signaling activation in intrahepatic cholangiocarcinoma
(ICC) from AKT/Yap mice. a Notch signaling activation at tran-
scriptional level is presented by qPCR. Data are analyzed and nor-
malized using the −ΔΔCt method and presented as mean ± SD; NL
represents normal liver; n= 6, *p < 0.05; **p < 0.01; ***p < 0.001. b
Western blot analysis of relative protein expression in normal liver and
tumor samples. GAPDH was used as a loading control. c Hematoxylin
and eosin (H&E) staining and immunohistochemistry (IHC) of AKT/
Yap-induced tumors. CK19 and Ki67 showed the ICC nature and the
proliferative features of these tumors, respectively. Notch2 immuno-
labeling was localized in the cytoplasm and nucleus of ICC cells.
Notch1 positive cells exhibited the same staining pattern of CD34
positive cells, which are mostly endothelial cells. Magnification: 200×;
Scale bar: 100 µm
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Fig. 3 Intrahepatic cholangiocarcinoma (ICC) formation depends on
canonical Notch pathway in AKT/Yap mice. a Study design. b Gross
image of livers from each group. c Survival analysis of mice bearing
AKT/Yap/pT3 (n= 5) and AKT/Yap/dnRBPJ (n= 5) tumors as
assessed by the Kaplan–Meier survival method. d Upper panels show
H&E and immunohistochemistry of AKT/Yap/pT3 mice, and lower
panels that of AKT/Yap/dnRBPJ mice, respectively. Scale bar: 100 μm
for 200×; 50 μm for 400×. e The percentage of Ki67 positive cells in
the two groups (n= 5 per each cohort) was analyzed using Image Pro
Plus. f Percentage of CK19 positive area in the two groups is dis-
played. Area fraction was analyzed with the ImageJ software; n= 3
per each group. g Relative mRNA expression of AFP and GPC3 was
analyzed and normalized using the −ΔΔCt method. h Relative
expression of Notch target genes is shown. All data are presented as
mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001
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biliary cell fate of not only embryonic hepatoblasts, but also
mature hepatocytes [22]. Furthermore, the expression of
Notch2 is more often observed in well-differentiated ICC,
indicating its role in biliary tumor cell differentiation [23].
In a recent study [24], we found that anti-Notch2 treatment
can reduce both HCC and ICC tumor load induced by AKT
and neuroblastoma RAS viral oncogene homolog (NRas)
oncoproteins, whereas Notch1 suppression decrease HCC
and augments ICC occurrence. This body of evidence
suggests the conflicting functions of Notch1 and Notch2
receptors in different contexts.
Formerly, most of the studies regarding Notch1 and
Notch2 receptors aimed at their overexpression rather than
their suppression. In the present study, we sought to better
define the cell functions of Notch1 and Notch2 receptors in
mice by loss-of-function experiments. Thus, we generated a
mouse model characterized by biliary trans-differentiation
of hepatocytes, and investigated whether this cellular event
depends on autocrine Notch1 or Notch2 signaling. Speci-
fically, we overexpressed activated forms of v-akt murine
thymoma viral oncogene homolog (myr-AKT) and yes-
associated protein (YapS127A) genes in hepatocytes by
hydrodynamic injection (AKT/Yap) [25]. By adopting
lineage tracing technology [6], we show that AKT/Yap-
induced ICC formation is hepatocyte derived and this pro-
cess depends on the canonical Notch signaling pathway.
Furthermore, we found that Notch2 is the major driver of
the biliary phenotype in AKT/Yap tumors, whereas inacti-
vation of Notch1 slightly delays tumor development with-
out affecting the histological features of AKT/Yap ICC
lesions.
Results
AKT/Yap-induced ICCs originate from hepatocytes
To determine whether ICC cells induced by AKT/Yap co-
expression originate from mature hepatocytes, we applied
the hepatocyte fate tracing model as previously described
[6, 26]. Specifically, we injected adeno-associated virus
encoding Cre-recombinase under the control of hepatocyte-
specific thyroxine-binding globulin (Tbg) promoter (AAV8-
Tbg-Cre) into mice that carry EYFP disrupted by a floxed
stop codon in the ubiquitously expressed Rosa26 locus
(R26R-EYFP mice). This procedure leads to the activation
of hepatocyte-specific EYFP expression after 1 week of
AAV injection. We applied hydrodynamic tail vein injec-
tion of hemagglutinin (HA) tagged AKT and YapS127
plasmid (AKT/Yap), along with Sleeping Beauty (SB)
plasmids to initiate ICC development (Fig. 1a). Immuno-
fluorescence (IF) staining showed that all tumor cells were
positive for the BEC marker CK19, hepatocyte lineage
marker EYFP, as well as ectopically expressed HA tagged
AKT (Fig. 1b). The results demonstrate that AKT/Yap co-
expression induces hepatocyte-derived ICCs in the mouse
liver.
Notch signaling cascade is activated in AKT/Yap ICC
As the canonical Notch signaling has been implicated in
cholangiocarcinogenesis [14, 27], especially hepatocyte-
derived ICC formation [6, 7], we evaluated whether the
Notch cascade is activated in AKT/Yap ICC tumors. We
found that AKT/Yap ICCs express higher mRNA levels of
Notch receptors (Notch1 and Notch2), Notch ligands (Jag-
ged1 and Jagged2), and canonical Notch target genes (Hes1,
Hes5, Hey1, Hey2, and HeyL) when compared to normal
liver (Fig. 2a). Western blot analysis confirmed the upre-
gulation of Notch1, Notch2, Jag1 as well as the BEC
marker Sox9 in AKT/Yap tumors (Fig. 2b). To further
characterize the specific cell type(s) within the tumors that
express Notch receptors, Notch1 and Notch2 immunohis-
tochemistry (IHC) was performed. We observed Notch2
immunoreactivity in the cytoplasm and nucleus of tumor
cells, with no Notch2 expression being detected in
mesenchymal cells. In contrast, Notch1 immunolabeling
could be easily observed in cells surrounding the tumor
nodules, similar to that of CD34, which marks endothelial
cells (ECs) (Fig. 2c). Upon longer DAB (3,3′-diamino-
benzidine) incubation time, we could detect weak cyto-
plasmic and/or membranous staining of Notch1 in tumor
cells, as well as in surrounding non-neoplastic hepatocytes
(Sup Fig. 1).
Altogether, our data underline the activation of the Notch
cascade in AKT/Yap ICC. Specifically, Notch2 is strongly
expressed in ICC cells, whereas Notch1 is predominantly
expressed in the cells of the tumor microenvironment.
AKT/Yap-induced ICC depends on the canonical
Notch pathway
Next, we tested whether the canonical Notch pathway is a
major pathogenic player in AKT/Yap-driven cholangio-
carcinogenesis. For this purpose, we co-expressed AKT and
Yap plasmids with a dominant negative form of recombi-
nation signal-binding protein for immunoglobulin kappa J
(dnRBPJ) in FVB/N mice, which will be referred to as
AKT/Yap/dnRBPJ (Fig. 3a). RBPJ is a downstream tran-
scription factor that constitutes the DNA-binding site of the
Notch transcription complex. Expression of dnRBPJ has
been shown to effectively block the canonical Notch sig-
naling [28, 29]. Additional mice were injected with AKT
and Yap with pT3-EF1α empty vector as control (AKT/
Yap/pT3) (Fig. 3a). Of note, we found that blocking the
canonical Notch cascade significantly delayed AKT/Yap-
Notch2 as determinant in cholangiocarcinoma formation 3233
induced liver tumor formation and prolonged mouse sur-
vival (Sup Fig. 2 and Fig. 3b,c). Consistently, Ki67 index
significantly decreased in AKT/Yap/dnRBPJ liver tumors
when compared to that in AKT/Yap/pT3 liver tumors (Fig.
3d,e), implying that tumor cell proliferation was down-
regulated by blocking the canonical Notch signaling. Most
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importantly, histological analysis revealed that while AKT/
Yap/pT3 tumors consisted of pure ICC, as also indicated by
strong immunoreactivity for the CK19 biliary marker (Fig.
3d,f), AKT/Yap/dnRBPJ liver tumors consisted mostly of
hepatocellular adenomas and few HCC lesions. These
observations were further underscored by increased levels
of tumor hepatocellular markers, such as alpha-fetoprotein
(AFP) and glypican 3 (GPC3), in AKT/Yap/dnRBPJ tumors
(Fig. 3g). As expected, the downstream targets of the Notch
signaling were down-regulated in AKT/Yap/dnRBPJ mice
(Fig. 3h), thus substantiating the effective blockade of this
cascade by dnRBPJ overexpression.
Taken together, our study demonstrates that the canoni-
cal Notch signaling is required for AKT/Yap-induced
hepatocyte-derived ICC formation in mice.
Limited effects of cell autonomous Notch1 signaling
in AKT/Yap-induced ICC formation in mice
Next, we investigated whether Notch1 or Notch2 was the
major Notch receptor mediating AKT/Yap-induced ICC
development. As our study shows the low expression of
Notch1 in normal hepatocytes and ICC tumor cells (Sup
Fig. 1), we first investigated the cell autonomous role of
Notch1. Thus, Notch1flox/flox mice were hydrodynamically
injected with AKT, YapS127A, and pCMV/Cre plasmids to
allow the expression of AKT/Yap oncogenes in Notch1
knockout hepatocytes (AKT/Yap/Cre; Sup Fig. 3).
Notch1flox/flox mice injected with AKT, Yap, and pCMV
(empty vector) were used as control (AKT/Yap/pCMV; Sup
Fig. 3). Hepatocyte-specific ablation of Notch1 delayed
AKT/Yap-induced liver tumor development (Fig. 4a,b).
qRT-PCR and Western blot analyses demonstrate that
Notch1 mRNA and protein expression were both lower in
AKT/Yap/Cre mouse liver tumors than that in control AKT/
Yap/pCMV tumors (Fig. 4c,d). However, substantial
Notch1 expression could still be observed in AKT/Yap/Cre
tumors, suggesting that most of Notch1 was not expressed
in tumor cells, but in other cell types within the ICC lesions.
Consistent with this observation, IHC revealed that Notch1
could still be detected in AKT/Yap/Cre mouse liver tumors,
and most likely in CD34(+) ECs (Fig. 4e). Histological
analysis showed that tumor-specific ablation of Notch1 did
not change tumor morphology: indeed, ICC lesions were
found throughout the liver and no hepatocellular tumors,
including hepatocellular adenoma and HCC, were observed
in both AKT/Yap/Cre and AKT/Yap/pCMV Notch1flox/flox
mice (Fig. 4e). The overall ICC tumor burden, as measured
by the percentage of CK19(+) liver area, did not differ in
the two cohorts (Fig. 4f). Similarly, no difference in cell
proliferation was observed (Fig. 4g). Finally, loss of Notch1
in tumor cells did not affect the protein expression of
Notch2, Jag1, and BEC marker Sox9 as well as mRNA
levels of Notch targets, including Hes5 and Hey2 (Fig. 4c,d,
h). Loss of Notch1 instead decreased the expression of
Hes1, Hey, and HeyL (Fig. 4h).
In summary, our study demonstrates that Notch1
expression is low in AKT/Yap tumor cells, and ablation of
Notch1 in hepatocytes delays ICC tumorigenesis. However,
the cell autonomous Notch1 signaling is neither a major
determinant of activated canonical Notch cascade nor the
key driver for AKT/Yap-induced ICC development in mice.
Cell autonomous Notch2 deprivation is required for
AKT/Yap-induced ICC development in mice
In light of the pivotal role of Notch2 signaling in biliary cell
fate determination [22], we investigated the function of
Notch2 in AKT/Yap ICC lesions using conditional
Notch2flox/flox mice (Sup Fig. 4). Specifically, we hydro-
dynamically injected AKT, Yap, and Cre into Notch2flox/flox
mice (AKT/Yap/Cre). Notch2flox/flox mice injected with
AKT, Yap, and pCMV empty vector (AKT/Yap/pCMV)
were used as control. Ablation of Notch2 significantly
delayed AKT/Yap-induced ICC development in mice,
although eventually all mice developed lethal burden of
liver tumors and were required to be euthanized (Fig. 5a,b).
Histologically, ICC lesions could be found throughout the
liver parenchyma of AKT/Yap/pCMV mice, while no
hepatocellular lesions were identified. Strikingly, ablation
of Notch2 resulted in mostly hepatocellular adenomas with
some HCC lesions in the liver, while no ICC lesions could
be detected (Fig. 5c). These findings were further validated
via IHC of BEC marker CK19 and hepatocyte-specific
marker HNF-4α (Fig. 5c,d). Proliferation of tumor cells was
significantly reduced following Notch2 depletion, as indi-
cated by Ki67 index (Fig. 5e). Western blot analysis con-
firmed the loss of Notch2 in the liver tumor lesions (Fig. 5f).
In addition, mRNA levels of the canonical Notch targets,
including Hes1, Hes5, Hey1, Hey2, and HeyL were
Fig. 4 Notch1 inactivation does not prevent ICC formation in AKT/
Yap mice. a Gross images of livers from AKT/Yap/pCMV and AKT/
Yap/Cre mice. b Survival analysis of Notch1flox/flox mice bearing AKT/
Yap/pCMV (n= 10) and AKT/Yap/Cre (n= 10) tumors using the
Kaplan–Meier survival method. c Relative mRNA expression of
Notch1 and Notch2 was analyzed and normalized using the −ΔΔCt
method and presented as mean ± SD; NL represents normal liver; n=
6. d Western blot analysis of normal liver, AKT/Yap/pCMV, and
AKT/Yap/Cre mice. GAPDH was used as a loading control. e H&E
and immunohistochemical staining of AKT/Yap/pCMV (upper panels)
and AKT/Yap/Cre (lower panels) mice. Several sections were enlarged
for a better view on the expression of Notch1, CD34, and Vimentin.
Scale bar: 100 μm for 200×; 50 μm for 400×. f Quantification of CK19
+ area percentage is displayed, n= 4. g Percentage of Ki67 positive
nuclei was analyzed in normal liver (n= 5), AKT/Yap/pCMV (n= 5),
and AKT/Yap/Cre (n= 5) mice. h Relative expression of Notch target
genes is shown; n= 6. All data are presented as mean ± SD. ns p >
0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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remarkably dowregulated following Notch2 deletion, as
assessed by qRT-PCR analysis (Fig. 5g,h). These data
indicate that Notch2 is the major regulator of the canonical
Notch cascade in this mouse model. Interestingly, Notch1
expression was also decreased upon Notch2 ablation (Fig.
5f,g). Immunolabeling of CD34 and Vimentin in the tumor
sections revealed that ECs and fibroblast cells were less
numerous in AKT/Yap/Cre lesions (Fig. 5c). Since Notch1
is most likely expressed dominantly in ECs, the reduced
ECs may account for the decreased Notch1 expression in
AKT/Yap/Cre lesions.
Recent experimental data point to the JNK signaling as a
critical modulator of biliary differentiation and proliferation
[30]. Accordingly, we found that the JNK pathway was
effectively inactivated following Notch2 (Fig. 5f) but not
Notch1 (Fig. 4d) deletion, thus suggesting that the JNK
cascade could be a crucial downstream effector of Notch2 in
ICC.
Altogether, these data indicate that Notch2 is essential
for Akt/Yap-induced ICC development.
Deletion of Notch2 undermines the biliary
properties in vitro
The studies in mice suggest the possibility that Notch2
controls BEC-like cell fate in human liver tumor cells. Thus,
we tested whether silencing of Notch2 affected BEC marker
expression in human HCC and ICC cell lines. A total of
three ICC cell lines (KKU-M213, HuCC-T1, and RBE) and
three HCC cell lines (HLE, SNU-449, and SNU475) were
transfected with scrambled control siRNA or siNotch2. As
expected, Notch2 expression was impaired following
siNotch2 treatment in both ICC and HCC cell lines (Fig. 6a,
b). Also, knockdown of Notch2 was paralleled by decreased
SOX9 expression as well as by decline of canonical Notch
targets, including Hes1, Hey1, and Nrarp (Fig. 6c).
Transcriptional levels of Epcam were significantly reduced
in all HCC cell lines and two ICC cell lines.
In summary, our study indicates that Notch2 expression,
at least partially, controls BEC fate gene expression in
human HCC and ICC tumor cells.
Discussion
ICC is a malignant form of liver tumor lacking effective
treatment options. The cellular origin of ICC is currently a
matter of debate. Previously, it was believed that ICC arises
from BEC of the liver. This is most likely the case in
patients where a predisposing risk factor is limited to the
biliary ducts, such as infections by Clonorchis sinensis,
choledocholithiasis, or choledochal cysts. However, in
Western and East Asian countries, where inflammatory
processes affecting the biliary tract are uncommon, HBV
and HCV infection and alcohol abuse are the main risk
factors for ICC, as for HCC [5]. Since HBV and HCV
viruses do not infect BECs, how ICC develops in the
context of chronic hepatocyte injury remains a matter of
debate. Presumably, hepatocytes are the cells of origin of
this subset of human ICCs. Previous studies have shown the
extraordinary plasticity of mature hepatocytes, which can
transdifferentiate into BECs upon injury [4, 31, 32]. In the
presence of additional oncogenic and/or mutagenic stimuli,
it is possible that these trans-differentiated BECs further
transform into ICC cells. Besides hepatocytes, several other
cell types can also undergo trans-differentiation, leading to
cancer formation [33]. One of such examples is pancreatic
ductal adenocarcinoma (PDAC) [34, 35]. Like ICC, PDAC
was thought to originate from ductal cells within the pan-
creas. However, recent studies have challenged this
assumption, showing that acinar cells (the major par-
enchymal cells in the pancreas) are able to transdifferentiate
into ductal cells. This process, also known as acinar-to-
ductal metaplasia, can facilitate pancreas regeneration after
injury [34, 35]. These metaplastic cells have been found to
be precursors of pre-neoplastic PanIN lesions, which can
further progress to PDAC [34, 35]. In this study, we show
that AKT/Yap-induced ICCs arise from mouse hepatocytes.
Our previous investigation has demonstrated the frequent
concomitant activation of AKT and Yap signaling cascades
in human ICCs [25]. Thus, we believe that the AKT/Yap
mouse model is highly relevant to study human cho-
langiocarcinogenesis, especially in the context of chronic
liver injury where hepatocytes may in fact be the target of
transformation.
The molecular mechanisms underlying the development
of hepatocyte-derived ICC remain poorly understood. Pre-
vious studies from our and other groups identified the
canonical Notch cascade as a critical driver in hepatocyte-
Fig. 5 Notch2 inactivation suppresses ICC development in AKT/Yap
mice. a Gross images of AKT/Yap/pCMV and AKT/Yap/Cre livers. b
Survival analysis of Notch2flox/flox mice bearing AKT/Yap/pCMV (n=
9) and AKT/Yap/Cre (n= 9) tumors. c H&E and immunohistochem-
istry of AKT/Yap/pCMV (upper panels) and AKT/Yap/Cre (lower
panels) mice. Several sections were enlarged for optimal vision. Scale
bar: 100 μm for 200×; 50 μm for 400×. d CK19 staining was quantified
and represents the percentage of positive staining area of the whole
area in the two groups, n= 4. e Percentage of Ki67 positive cells was
analyzed in normal liver (n= 5), AKT/Yap/pCMV (n= 6), and AKT/
Yap/Cre (n= 6) livers. f Western blotting of normal liver, AKT/Yap/
pCMV, and AKT/Yap/Cre livers in Notch2flox/flox mice. GAPDH was
used as a loading control. g Relative expression of Notch1 and Notch2
using qPCR. Data were analyzed and normalized using the −ΔΔCt
method, n= 6. h Relative expression of Notch signaling target genes
using qPCR; n= 6. All data are presented as mean ± SD. ns p > 0.05;
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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derived ICC [6, 7]. However, all these studies were based
on gain of function of Notch receptors, aiming to demon-
strate that activation of Notch is sufficient to promote ICC
formation. Whether Notch is required for hepatocyte-driven
ICC development, and if so, which Notch receptor is
responsible for this process have not been previously
investigated. In this study, by co-expressing AKT and Yap
oncogenes with dnRBPJ, which blocks the canonical Notch
cascade [28, 29], we convincingly proved that the endo-
genous Notch signaling is required for hepatocyte-derived
ICC. It is worth to note that Notch was found to be required
for acinar-to-ductal metaplasia in a KRas-driven PDAC
murine model [36]. In addition, a recent study showed that
activation of endogenous Notch leads to trans-
differentiation of neuroendocrine to non-neuroendocrine
cells in small-cell lung cancer cells [37]. Together these
studies point to Notch signaling as an important cell-fate
determinant in multiple tumor types.
Furthermore, we investigated which Notch receptor is
responsible for Notch-dependent-ICC development, focus-
ing on Notch1 and Notch2 receptors. Using conditional
Notch1 and Notch2 KO mice, we demonstrated that loss of
Notch1 only moderately delays AKT/Yap ICC develop-
ment. However, ICC lesions eventually occurred in all
Fig. 6 Inactivation of Notch2 in human intrahepatic cholangiocarci-
noma (ICC) and hepatocellular carcinoma (HCC) cell lines. a and b
Western blot analysis shows the complete inhibition of Notch2
expression in ICC and HCC cell lines transfected with siNotch2.
Control is presented as ctr and siNotch2 group is indicated as si.
GAPDH was used as a loading control; n= 3. c qPCR analysis of
Notch2, Nrarp, Epcam, Hes1, and Hey1. Data are analyzed and nor-
malized using the −ΔΔCt method, n= 3. All data are presented as
mean ± SD. ns p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001
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mouse livers depleted of Notch1. In striking contrast, when
Notch2 was knocked-out in hepatocytes, not only it led to
delayed tumor development, but also resulted in the
exclusive formation of hepatocellular adenoma and HCC-
like lesions, thus recapitulating the phenotype observed
following the inhibition of the canonical Notch signaling.
These observations indicate that the cell autonomous
Notch2 is required for hepatocyte–BEC trans-differentiation
and ICC formation in mice. In addition, using human HCC
and ICC cell lines, we showed that silencing of Notch2
decreased the expression of the BEC marker Sox9. We then
analyzed Notch2 expression in relationship to Sox9 in a
human TCGA dataset containing 59 non-tumor livers and
36 human ICC samples [38]. Importantly, a statistically
significant correlation between Notch2 and Sox9 expression
in all liver samples, as well as in ICC tumors was found
(Sup Figs. 5A and 5B). Furthermore, analysis of the cBio-
Portal for Cancer Genomics dataset [39] revealed Notch2
amplification in 4/36 (11%) human ICC specimens, whereas
no alterations were identified for Notch1 (Sup Fig. 5C). In
humans, loss-of-function mutations in Notch2 or its ligand
Jagged1 are associated with Alagille Syndrome, a devel-
opmental disorder leading to bile duct scarcity [40, 41].
These data support the prominent role of Notch2 in BEC
differentiation and bile duct formation during development,
and are consistent with the hypothesis that Notch2 may also
control the BEC fate along human cholangiocarcinogenesis.
The mechanisms whereby Notch2 promotes BEC differ-
entiation and ICC development remain to be better deli-
neated. Interestingly, the importance of the JNK signaling in
biliary carcinogenesis has been recently demonstrated [30].
Of note, we found that the JNK pathway is impaired in
Notch2-depleted livers (Fig. 5f), thus suggesting a func-
tional crosstalk between these two cascades during ICC
formation and/or progression. Additional investigation is
necessary to unravel the function of the JNK signaling
downstream of Notch2 in cholangiocarcinogenesis.
Unlike Notch2, the functional role of Notch1 in intra-
hepatic cholangiocarcinogenesis remains poorly under-
stood. Using conditional Notch1 KO mice, we showed that
loss of Notch1 in tumor cells delays AKT/Yap-induced
tumor development and mildly reduces the levels of a
subset of Notch target genes. These results suggest that the
contribution of Notch1 receptor to hepatocyte-derived ICC
formation in mice might be limited. Intriguingly, IHC
revealed that Notch1 is predominantly expressed in the
tumor microenvironment (Figs. 2c and 4e). This staining
pattern in AKT/Yap lesions is consistent with that in AKT/
Ras liver tumors [24]. However, due to the low sensitivity
of the anti-Notch1 antibody, we were unable to convin-
cingly conclude whether Notch1 is expressed in ECs or
tumor-associated fibroblast cells. Further studies, using
single cell RNA-Seq analysis for instance, will be required
to identify the cell types expressing Notch1. Furthermore,
using proper cell-lineage Cre mouse lines in combination
with conditional Notch1 KO mice, it would be possible to
unravel the precise mechanisms whereby Notch1 plays a
role in cholangiocarcinogenesis. For instance, Lrat-Cre
mice express Cre in fibroblasts, including hepatic stellate
cells [42], and they can be used to delete Notch1 in ICC-
associated fibroblasts. Also, Tie2-Cre mice [43] could be
used to delete Notch1 in ECs. In summary, our investigation
suggests that Notch1 acts in a paracrine fashion to regulate
ICC development.
Finally, our study has important clinical implications.
Targeting Notch has been proven highly toxic in tumor
patients mainly at the gastrointestinal level to date, pre-
sumably due to the important physiological roles of various
Notch-related proteins [14]. The present findings suggest
that Notch2 might be a potential target in human ICC. Of
note, promising anti-neoplastic effects by Notch2-specific
antibodies were detected in ICC lesions from AKT/Ras
mice [24]. Thus, further studies should be conducted to
establish the eventual relevance of anti-Notch2 strategies for
the treatment of this deadly disease.
Materials and methods
Constructs and reagents
We used constructs as described previously, including pT3-
EF1α, pT3-EF1α-HA-myr-AKT (mouse), pT3-EF1α-
YapS127A (human), pT3-EF1α-dnRBPJ (human), pCMV,
pCMV-Cre, and pCMV/SB transposase [28, 44–46].
Adeno-associated virus encoding Cre-recombinase under
the control of hepatocyte-specific thyroxine-binding glo-
bulin (Tbg) promoter (AAV8-Tbg-Cre) was provided by the
University of Pennsylvania Vector Core (Philadelphia, PA).
All plasmids were purified utilizing the Endotoxin Free
Maxi prep kit (Sigma- Aldrich, St. Louis, MO).
Animals
We obtained R26R-EYFP mice from Jackson Laboratory
(Sacramento, CA, USA). Five female R26R-EYFP mice
were injected with AAV8-Tbg-Cre. HA tagged AKT,
YapS127 plasmid (AKT/Yap), and SB were delivered to the
mice by hydrodynamic injection. FVB/N and Notch2flox/flox
mice were purchased from Jackson Laboratory. Notch1flox/
flox mice were a generous gift by Dr. Rong Wang at UCSF.
Five female FVB/N mice were injected with AKT/Yap
hydrodynamically; 10 male mice were randomly assigned
to AKT/Yap/pT3 and AKT/Yap/dnRBPJ groups. A total of
9 female and 9 male Notch2flox/flox mice were randomly
assigned to AKT/Yap/pCMV and AKT/Yap/Cre groups.
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Finally, 7 female and 13 male Notch1flox/flox mice were
randomly assigned to AKT/Yap/pCMV and AKT/Yap/Cre
cohorts. The study was not blinded.
Hydrodynamic tail vein injection
We employed hydrodynamic injection as previously
described in detail [47]. The dosage of pT3-EF1α-HA-myr-
AKT (AKT) and pT3-EF1α-YapS127A (Yap) plasmids was
20 and 30 μg, respectively. To suppress the canonical Notch
signaling, we applied 60 μg pT3-EF1α-dnRBPJ or 60 μg
pT3-EF1α together with AKT and Yap plasmids in FVB/N
mice. In transgenic models, we injected 60 μg pCMV-Cre or
60 μg empty pCMV vector together with AKT/Yap. Mice
were housed, fed, and monitored according to protocols
approved by the Committee for Animal Research at the
University of California San Francisco (San Francisco, CA).
Histology, IHC and IF
Samples were fixed overnight with Zinc Formal-Fixx
(Thermo Shandon Limited, Runcorn) at 4 °C for sub-
sequent paraffin-embedding. Sections were done at 5 μm in
thickness. For IHC of HNF-4α, antigen unmasking was
performed in Tris/EDTA buffer (pH 9.0), while for all other
targets in sodium citrate buffer (pH 6.0). Other information
could be found in the Supplementary Material and Methods.
Protein extraction and western blot analysis
Specific protein extraction procedures can be found in
Supplementary Material and Methods. Aliquots of 30 μg
lysate were denatured by boiling in Tris–Glycine SDS
Sample Buffer (Invitrogen, Grand Island, NY). We used
SDS-PAGE for protein separation. And then protein was
transferred onto nitrocellulose membranes (Invitrogen).
Membranes were blocked in 5% non-fat dry milk in Tris-
buffered saline containing 0.1% Tween 20 for 1 h and
incubated with specific primary antibodies (Supplementary
Table 1). Subsequently, a horseradish peroxidase-secondary
antibody diluted 1:10,000 for 1 h was applied and revealed
using the Super Signal West Pico Chemiluminescent Sub-
strate (Pierce Chemical Co., New York, NY).
RNA extraction and qPCR
We extracted total mRNA from liver tissues and cells using
the Quick RNA miniprep kit (Zymo Research, Irvine, CA,
USA). Next, mRNA expression was detected by qRT-PCR
using SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA) in an QuantStudio™ 6 Flex system
(Applied Biosystems). Expression of each gene was nor-
malized with the 18S rRNA. Other conditions can be found
in Supplementary Material and Methods. The list of primers
is reported in Supplementary Table 2.
Cell culture studies
We obtained the KKU-M213 and RBE ICC cell lines from
the Japanese Collection of Research Bioresources Cell Bank
(JCRB, Japan) and RIKEN cell bank (Tsukuba, Japan),
respectively. HuCC-T1 was a generous gift by Dr. Gregory
J. Gores (Mayo Clinic, Rochester, MN). HLE, SNU-449,
and SNU-475 HCC cell lines were purchased from Amer-
ican Type Culture Collection (ATCC, Manassas, VA,
USA). All cells were authenticated and tested clear of
mycoplasma contamination. Cells were cultured separately
in DMEM medium (Gibco, Grand Island, NY, USA) with
5% fetal bovine serum (Gibco), 100 μg/ml streptomycin,
and 100 U/ml penicillin at 37 °C in 5% CO2 humidified
incubator.
In vitro siRNA transfection
KKU-M213, HuCC-T1, RBE ICC cell lines, and HLE,
SUN-449, SNU-475 HCC cells were transfected with short
interfering RNAs (siRNAs) targeting Notch2 (Thermo
Fisher Scientific) or negative control siRNA (Thermo Fisher
Scientific) using Lipofectamine RNA/iMAX (Thermo
Fisher Scientific). Cells were harvested after 48 h for qPCR
and Western blot analysis.
Statistical analysis
The Prism 7.0 software (GraphPad, San Diego, CA) was
used to analyze the data, which are presented as Means ±
SD. Comparisons between two groups were performed with
two-tailed unpaired t test. Welch correction was applied
when necessary. P values < 0.05 were considered statisti-
cally significant.
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